Amarin Corp Plc (AMRN)

[couldbebetter]

alm2, This clearly places AMRN at a crossroad. Either JT will sell the
company (mainly for the value of Europe at this point,) or else he will
develop a branded generic Vascepa to counter the launch of a generic
Vascepa as well as establish a sales force in Europe. Perhaps he will
continue with the later while he leaves open the prospect of the former.

I honestly don't know if a branded Vascepa launch is even viable as from
what has been posted previously generics are generally selected based
on the relationship they have with pharmacy chains. Europe should be
left to those BP with long standing relationships there. Common sense
dictates that if AMRN truly GIA in Europe will be an uphill struggle.
What would be the point when sales reps and structures are already in
place?

The most logical solution is to sell the company...something which
should have been done long ago. Perhaps there is a BP that would
be a position to offer a branded generic Vascepa along with their
other generic offerings and have relationships with pharmacies.
My fear right now is that JT will attempt GIA!